Business
Inside information: Bioretec Ltd's Board of Directors resolved on a rights issue of up to approximately EUR 14.8 million and publishes the terms and conditions of the rights issue
The Board of Directors of Bioretec Ltd ("Bioretec" or the "Company") has today 27 March 2026, based on the authorisation of the Extraordinary General Meeting of the Company held on 27 March 2026, resolved to offer Bioretec's shareholders up to 1,477,828,416 new shares (the "New Shares") for subscription primarily on the basis of shareholders' pre-emptive subscription right in the same proportion as they already hold shares in the Company (the "Existing Shares") and secondarily by other sharehold
About this update from Bioretec Ltd.
[{"type":"text","content":"Bioretec Ltd Inside information 27 March 2026 at 12:50 p.m. EET","length":78,"tagName":"p"},{"type":"text","content":"NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.","length":351,"tagName":"p"},{"type":"text","content":"HELSINKI, March 27, 2026 /PRNewswire/ -- The Board of Directors of Bioretec Ltd ("Bioretec" or the "Company") has today 27 March 2026, based on the authorisation of the Extraordinary General Meeting of the Company held on 27 March 2026, resolved to offer Bioretec's shareholders up to 1,477,828,416 new shares (the "New Shares") for subscription primarily on the basis of shareholders' pre-emptive subscription right in the same proportion as they already hold shares in the Company (the "Existing Shares") and secondarily by other shareholders or by other persons in a rights issue of up to approximately EUR 14.8 million (the "Offering"). The subscription price for each New Share is EUR 0.01 (the "Subscription Price").","length":795,"tagName":"p"},{"type":"text","content":"The purpose of the Offering is to strengthen the Company's capital base and financing resources supporting the Company in the execution of its strategy announced by a company release on 16 December 2025. The Company aims to strengthen its balance sheet, ensure sufficient working capital and finance the working capital needs of its targeted business growth with the proceeds from the Offering. The proceeds raised in the Offering are intended to be used to advance the commercial scale-up of the Company's products particularly in the United States, continue the progression of the development pipeline and launch three new products within the next 18 months, improve the Company's operations and production capabilities, and for working capital and general administration expenses.","length":795,"tagName":"p"},{"type":"text","content":"The Offering in brief","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In the Offering, Bio...